For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Budget 2024: Extension of breast screening election promise is being fulfilled
Budget 2024: Extension of breast screening election promise is being fulfilled

Ah-Leen Rayner, chief executive of Breast Cancer Foundation NZ, said: “The $31.2 million to gradually extend free breast screening will give older women the best chance of having their breast cancer diagnosed early, so it’s excellent news this election promise is being fulfilled and we’re eager to understand how and when it will be rolled out.
“However, the lack of funding for new cancer drugs leaves some breast cancer patients in an untenable situation while the Government kicks the medicines crisis down the road. The previously-announced $1.77 billion is only enough to continue the availability of existing treatments and doesn’t give access to any new ones.
“There are breast cancer drugs that Pharmac has assessed to be necessary and will fund if it has enough money. Without a substantial increase to Pharmac’s budget, women are still denied access to these essential treatments. This is not a problem that can be put off for another day or another Budget – we need to see urgent investment and transformational change to allow breast cancer patients timely access to the treatments they need.